Outcome of advanced epithelial ovarian cancer: a tertiary care centre study

Sakina Muslim Umrethwala; Sohel Shaikh; Tushar Tatyabe Palve; Komal Devnikar; Sejal Kulkarni

doi:10.18203/2320-1770.ijrcog20231529

Authors

Sakina Muslim Umrethwala Department of Obstetrics and Gynecology, Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India
Sohel Shaikh Department of Surgery, Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India
Tushar Tatyabe Palve Department of Obstetrics and Gynecology, Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India
Komal Devnikar Department of Obstetrics and Gynecology, Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India
Sejal Kulkarni Department of Obstetrics and Gynecology, Grant Medical College and Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20231529

Keywords:

Epithelial ovarian cancer, NACT, Chemotherapy, Debulking surgery, ACT

Abstract

Background: Ovarian cancer is the fourth most common cancer in Indian women with an incidence of 4.9 cases per 100,000. Epithelial ovarian cancer is a silent killer disease as it presents at an advanced stage with minimal signs and symptoms.

Methods: It is a type of research article. The present study was conducted in Department of Obstetrics and Gynecology, Cama and Albless Hospital, Mumbai, Maharashtra, India, from a period of January 2018 to July 2019, during which 53 cases of EOC were studied.

Results: Out of 53 cases of EOC, 45 cases were advanced stage EOC, they were either operated as PDS-ACT or NACT- IDS.

Conclusions: NACT is recommended wherein optimal cytoreduction appears unlikely, or in patients where upfront surgery is high risk and extensive causing high morbidity post-surgery. Places where there is non-availability of special surgical expertise and hospital resources, there too NACT-IDS is recommended.

Metrics

Metrics Loading ...

References

Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97:519-23.

Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer (IARC); 2013.

Ziebarth AJ, Landen CN, Alvarez RD. Molecular/genetic therapies in ovarian cancer: Future opportunities and challenges. Clin Obstet Gynecol. 2012;55:156-72.

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248-59.

Chiva LM, Castellanos T, Alonso S, Gonzalez-Martin A. Minimal macroscopic residual disease (0.1-1 cm). Is it still a surgical goal in advanced ovarian cancer? Int J Gynecol Cancer. 2016;26:906-11.

Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-53.

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): An open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386:249-57.

Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:3460-73.

Bray, Freddie and Ferlay, Jacques and Soerjomataram, Isabelle and Siegel, Rebecca L. and Torre, Lindsey A. and Jemal, Ahmedin, et al Global

cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries; 2018:68.

Ehdaivand S. WHO classification of ovarian neoplasms. PathologyOutlines.com website. Available at: https://www.pathologyoutlines.com/topic/ovarytumorwhoclassif.html. Accessed on 25th November 2019.

Doufekas K, Olaitan A. Clinical epidemiology of epithelial ovarian cancer in the UK. Int J Womens Health. 2014;6:537-45.

Prat J. FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. Journal of Gynecologic Oncology. 2015;26(2):87-9.

Maheshwari A, Kumar N, Gupta S, Rekhi B, Shylasree TS, Dusane R, et al. Outcomes of advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. Indian J Cancer. 2018;55:50-4.

Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019 Mar 23;393(10177):1240-253.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls. Gynecologic Oncology. 2003;90(1):75-82.

Smith LH, Morris CR, Yasmeen S, Parikh-Patel A, Cress RD, Romano PS. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer. 2005;104(7):1398-407.

Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. The Journal of the American Medical Association. 2004;291(22):2705-12.

Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecologic Oncology. 2003;90(2):390-6.

Gleicher N. Why are reproductive cancers more common in nulliparous women? Reprod Biomed Online. 2013;26(5):416-9.